Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907657 · ClinicalTrials.gov registry record · Phase 2
Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03907657 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 15 participants.
The verdict
NCT03907657, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)
Interventions
- DRUG Perflutren lipid microsphere
- DRUG Sulfur hexafluoride lipid microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2023-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907657
The ClinicalTrials.gov registry entry for NCT03907657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Perflutren lipid microsphere is the first listed.
NCT03907657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03907657 about?
NCT03907657 is a clinical study titled "Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau". The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)
What is the current status of trial NCT03907657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-09-23. Estimated completion is 2023-03-13.
What interventions are being tested in trial NCT03907657?
The interventions under investigation include: Perflutren lipid microsphere (DRUG), Sulfur hexafluoride lipid microspheres (DRUG).
Who is sponsoring clinical trial NCT03907657?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.